In a large clinical trial, people with advanced melanoma treated with nivolumab (Opdivo) and a new drug called relatlimab-which targets a protein called LAG-3-lived longer without their cancer getting worse than those treated only with nivolumab.īoth nivolumab and relatlimab are immune checkpoint inhibitors. ![]() People diagnosed with advanced melanoma may soon have a new treatment option that combines two immunotherapy drugs. Credit: Adapted from Journal for ImmunoTherapy of Cancer.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |